On Tuesday, Lineage Cell Therapeutics Inc (AMEX: LCTX) was -4.76% drop from the session before ,before settling in for the closing price of $1.47. A 52-week range for LCTX has been $0.84 – $1.61.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 119.78% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 5.56%. With a float of $187.49 million, this company’s outstanding shares have now reached $188.53 million.
In an organization with 75 employees, it is important to assess its efficiency.
Lineage Cell Therapeutics Inc (LCTX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lineage Cell Therapeutics Inc stocks. The insider ownership of Lineage Cell Therapeutics Inc is 0.55%, while institutional ownership is 48.04%. The most recent insider transaction that took place on Feb 08 ’24, was worth 100,001. In this transaction Director of this company bought 96,155 shares at a rate of $1.04, taking the stock ownership to the 158,801 shares. Before that another transaction happened on Feb 06 ’24, when Company’s Director bought 6,730,770 for $1.04, making the entire transaction worth $7,000,001. This insider now owns 41,666,255 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/30/2023, it has been observed that the corporation posted -$0.03 earnings per share (EPS) during the time that was better than consensus figure (set at -$0.04) by $0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 5.56% per share during the next fiscal year.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
You can see what Lineage Cell Therapeutics Inc (LCTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.12, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.12 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.13 million. That was better than the volume of 0.95 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 46.54%. Additionally, its Average True Range was 0.12.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 72.68%, which indicates a significant increase from 48.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.81% in the past 14 days, which was lower than the 82.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1759, while its 200-day Moving Average is $1.2104. However, in the short run, Lineage Cell Therapeutics Inc’s stock first resistance to watch stands at $1.4683. Second resistance stands at $1.5367. The third major resistance level sits at $1.6033. If the price goes on to break the first support level at $1.3333, it is likely to go to the next support level at $1.2667. Assuming the price breaks the second support level, the third support level stands at $1.1983.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
There are 188,534K outstanding shares of the company, which has a market capitalization of 263.94 million. As of now, sales total 8,950 K while income totals -21,490 K. Its latest quarter income was 2,090 K while its last quarter net income were -4,780 K.
